In 2025, pharmaceutical companies invested more than $130 million in federal lobbying, reflecting a substantial increase of nearly 23% compared to previous years.
This surge in lobbying expenditures highlights the growing influence of the pharmaceutical sector in shaping policy and regulatory environments.
Additionally, Bristol-Myers Squibb has entered into a partnership with a Chinese firm, marking a significant step in its global expansion efforts.